Ting-Fun MayLai – Aligning Special Population Needs With Recovery Oriented Systems of Care

Published July 10, 2013

Ting-Fun MayLai – Aligning Special Population Needs with Recovery Oriented Systems of Care –

US FDA approves Orexo drug to treat opioid addiction

Filed under: buprenorphine treatment

Suboxone and Subutex generated sales of roughly $ 1.3 billion in 2012. Orexo said opioid dependence affects nearly 5 million people in the United States and that only 20 percent receive treatment. The company said it expects peak sales of the drug to be …
Read more on Reuters AlertNet

FDA Approves New Treatment for Opioid Dependence

Filed under: buprenorphine treatment

The US Food and Drug Administration (FDA) has approved Zubsolv (buprenorphine/naloxone, Orexo AB) for maintenance treatment of opioid dependence. Zubsolv is a once-daily, sublingual tablet with a formulation of buprenorphine and naloxone that fully …
Read more on Medscape